Research and development
Driving scientific innovation to deliver the next generation of transformational medicines and vaccines for patients.
We deliver our long-term priorities of Innovation, Performance and Trust through each of our three businesses which discover, develop and manufacture innovative pharmaceutical medicines, vaccines and consumer healthcare products.
Our approach to Pharmaceutical Research and Development (R&D) focuses on science related to the immune system, the use of human genetics and advanced technologies, and is driven by the multiplier effect of Science x Technology x Culture. It will help us to accelerate the pace at which we develop and deliver transformational medicines, prioritizing those molecules with a higher probability of success and terminating less promising programs. It also enables us to increase our focus on specialty medicines in areas such as oncology.
In our Vaccines business, we balance our focus on a robust pipeline with the active life-cycle management of our existing vaccines, seeking to protect more people through expanding indications and delivering our vaccines to new geographies. Our Innovation ambition is to lead the industry by disrupting the discovery, development and manufacturing of vaccines. We will focus on accelerating key assets in our pipeline and looking at innovative technologies so that we can unlock potential in emerging fields. Using our industry-leading science, we will accelerate the delivery of our most promising assets to serve the greatest unmet medical need. We want to change the world with our science.
Our Consumer Healthcare R&D organization develops products in five categories: Oral Health, Pain Relief, Respiratory, Nutrition and Gastrointestinal and Skin Health. Our focus is on building a strong, competitive pipeline of consumer-led, science-based innovation. On 1 August 2019 we announced that we'd completed our transaction with Pfizer to combine our consumer healthcare businesses into a new world-leading Consumer Healthcare Joint Venture. Within three years of the closing of the transaction, we intend to separate the Joint Venture via a demerger. With our future intention to separate, the transaction also presents a clear pathway forward for us to create a new global Pharmaceuticals/Vaccines company, and a new world-leading Consumer Healthcare company.
Key facts about R&D at GSK
Over 16,000 people working across our three global businesses
Our adjusted R&D investment in 2019
Our Vaccines business has around 150 external scientific collaborations
Our approach to R&D lies in the multiplier effect of Science x Technology x Culture. We strongly believe that by getting these three things right, we will be able to deliver better medicines to more patients, faster than we do today."
Learn more about research and development at GSK
We invest in scientific and technical excellence to develop and launch a pipeline of new products that meet the needs of patients and payers.
What we're working on
We are strengthening our pipeline through a focus on science related to the immune system, the use of human genetics and advanced technologies.
Partnering with GSK
We are committed to working with partners to deliver the next generation of medicines, vaccines and consumer healthcare products.